Eli Lilly (NYSE:LLY) shares were on track to snap six straight sessions of losses on Thursday, as the stock rose 1.9% at $790 ...

Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.

Eli Lilly's business is growing fast, but it wasn't enough for analysts and investors. It also slashed its earnings guidance ...

Novo Nordisk (NVO) reported better than expected sales for its weight loss therapy Wegovy with its Q3 2024 financials on ...

Even with this partial rebound, Lilly's share price remains roughly 13% below the peak set in late August. Some investors ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

RCCC News Service SALISBURY — Rowan-Cabarrus Community College and its students recently benefited from involvement with Eli Lilly and Company and its annual Global Day of Service. Student ...

Lilly (NYSE: LLY) makes drugs including Mounjaro for type 2 diabetes and Zepbound for obesity. For 2023, it reported $34 ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...